In one embodiment of all aspects the antibody is not a bispecific, bivalent antibody comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2.

Another aspect as reported herein is an antibody as reported herein for use as a medicament.

Another aspect as reported herein is an antibody as reported herein for use in the treatment of an ocular vascular disease.

Another aspect as reported herein is an antibody as reported herein for use in the removal of one or more soluble receptor ligands from the eye.

Another aspect as reportined herein is use of an antibody as reported herein in the manufacture of a medicament for the treatment of eye diseases, especially of ocular vascular diseases.

Another aspect as reported herein is an antibody as reported herein for use in the transport of one or more soluble receptor ligands from the intravitreal space to the blood circulation.

Another aspect as reported herein is an antibody as reported herein for use in treating an eye disease.

Another aspect as reported herein is an antibody as reported herein for use in the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.

Another aspect as reported herein is an antibody as reported herein for use in the removal of one or more soluble receptor ligands from the eye.

Another aspect as reported herein is an antibody as reported herein for use in treating eye diseases, especially ocular vascular diseases.

Another aspect as reported herein is an antibody as reported herein for use in the transport of one or more soluble receptor ligands from the intravitreal space to the blood circulation.

- shows a lower serum concentration compared to corresponding bispecific antibody without the mutations in the Fc-region polypeptides (96 hours after intravitreal application in mice, which are mouse FcRn deficient, but hemizygous transgenic for human FcRn) (determined in assays as described in Example 6), and/or

- shows a similar (factor 0.8 to 1.2) concentration in whole right eye lysates compared to corresponding bispecific antibody without the mutations in the Fc-region polypeptides (in mice, which are mouse FcRn deficient, but hemizygous transgenic for human FcRn, 96 hours after intravitreal application in the right eye) (determined in assays as described in Example 6).

18. An antibody according to any one of claims 7 to 17 for use as a medicament.

19. An antibody according to any one of claims 7 to 17 for use in the treatment of an ocular vascular disease.

20. An antibody according to any one of claims 7 to 17 for use in the removal of one or more soluble receptor ligands from the eye.

21. Use of an antibody according to any one of claims 7 to 17 in the manufacture of a medicament for the treatment of eye diseases selected from ocular vascular diseases.

22. An antibody according to any one of claims 7 to 17 for use in the transport of one or more soluble receptor ligands from the intravitreal space to the blood circulation.

23. An antibody according to any one of claims 7 to 17 for use in treating an eye disease.

24. An antibody according to any one of claims 7 to 17 for use in the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.

25. An antibody according to any one of claims 7 to 17 for use in the removal of one or more soluble receptor ligands from the eye.

26. An antibody according to any one of claims 7 to 17 for use in treating eye diseases, especially ocular vascular diseases.

27. An antibody according to any one of claims 7 to 17 for use in the transport of one or more soluble receptor ligands from the intravitreal space to the blood circulation.

28. An antibody according to any one of claims 7 to 17 for use in transporting a soluble receptor ligand from the intravitreal space or the eye over the blood-ocular-barrier into the blood circulation.

29. Use of an antibody according to any one of claims 7 to 17 in the manufacture of a medicament for the transport of a soluble receptor ligand from the intravitreal space or the eye over the blood-ocular-barrier into the blood circulation.

30. A pharmaceutical formulation comprising the antibody according to any one of claims 7 to 17.

31. A pharmaceutical formulation comprising the antibody according to any one of claims 7 to 17 for use in the treatment of ocular vascular diseases.

32. Use of the antibody according to any one of claims 7 to 17 for the manufacture of a medicament for the treatment of ocular vascular diseases.

33. The pharmaceutical formulation according to any one of claims 30 to 31, characterized in that the antibody is to be administered via intravitreal application.